China Biologic Products Holdings, Inc.
CBPO
CBPO was delisted on the 20th of April, 2021.
84 hedge funds and large institutions have $1.29B invested in China Biologic Products Holdings, Inc. in 2020 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 26 increasing their positions, 28 reducing their positions, and 18 closing their positions.
392% more call options, than puts
Call options by funds: $29.8M | Put options by funds: $6.06M
75% more funds holding in top 10
Funds holding in top 10: 4 → 7 (+3)
0% more capital invested
Capital invested by funds: $1.29B → $1.29B (+$3.37M)
7% less repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 28
3% less funds holding
Funds holding: 87 → 84 (-3)
11% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 18
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SGCM
Sand Grove Capital Management
London,
United Kingdom
|
+$46.9M |
| 2 |
MCP
Maso Capital Partners
Hong Kong
|
+$44.6M |
| 3 |
Renaissance Technologies
New York
|
+$23.6M |
| 4 |
Millennium Management
New York
|
+$14.6M |
| 5 |
BP
BFAM Partners
Northpoint, Hong Kong,
Hong Kong
|
+$14.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
YCMGA
York Capital Management Global Advisors
New York
|
-$28.8M |
| 2 |
AII
AGF Investments Inc
Toronto,
Ontario, Canada
|
-$23.1M |
| 3 |
Man Group
London,
United Kingdom
|
-$16.2M |
| 4 |
Goldman Sachs
New York
|
-$10.2M |
| 5 |
Fidelity International
Hamilton,
Bermuda
|
-$4.41M |
CBPO Hedge Fund Activity: Q1 2020 in Review
84 of the 4,539 institutional investors tracked by Wall St. Rank reported a position in China Biologic Products Holdings, Inc. (CBPO) for Q1 2020, worth a combined $1.29B — up 0.26% from $1.29B a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of CBPO and 16 opened new positions — a net loss of 2 holders — while 28 trimmed existing stakes and 26 added.
The largest buyer was Sand Grove Capital Management, adding an estimated $46.9M. The largest seller was York Capital Management Global Advisors, cutting an estimated $28.8M.
- 84 institutional investors held China Biologic Products Holdings, Inc. (CBPO) as of Q1 2020, down from 87 in Q4 2019.
- Funds reported $1.29B of China Biologic Products Holdings, Inc. stock for Q1 2020, up 0.26% quarter-over-quarter.
- 16 funds opened new China Biologic Products Holdings, Inc. positions in Q1 2020 and 18 closed out, a net change of -2 holders.
- The largest China Biologic Products Holdings, Inc. buyer in Q1 2020 was Sand Grove Capital Management, an estimated $46.9M added.
- The largest China Biologic Products Holdings, Inc. seller in Q1 2020 was York Capital Management Global Advisors, an estimated $28.8M sold.
Based on aggregated 13F filings for Q1 2020.